3Vaccination and Meningitis Prophylaxis

Pneumococcal cover before implantation

PCV (conjugate, e.g. PCV13/PCV15) is given first. It primes T-cell memory, so it is the foundation dose of the sequence.

Cochlear-implant recipients carry a raised risk of pneumococcal meningitis, so CDC/ACIP guidance pairs the conjugate vaccine (PCV, given first) with the polysaccharide vaccine (PPSV23) about 8 weeks later, completing the course at least 2 weeks before implantation. The interval is compressed and surgery never delayed in CSF-leak or immunocompromised patients, where the meningitis hazard is highest. Illustrative.

Relative meningitis risk (× baseline)

Reefhuis 2003 found implanted children had bacterial meningitis on the order of ~30× the general-population rate.

Reefhuis’ 2003 study showed cochlear-implant recipients carry a markedly higher rate of bacterial meningitis than other children — on the order of ~30× baseline — with the now-withdrawn positioner device higher still. Pneumococcal vaccination sharply lowers this risk but does not abolish it, so vigilance for warning signs remains essential. Illustrative, anchored in Reefhuis 2003.

Meningitis warning signs — tap any that appear

In any implant recipient, these signs — especially together — demand immediate emergency assessment; bacterial meningitis can progress within hours. Pneumococcal vaccination lowers but does not eliminate the risk, so families must still recognise the warning signs. Early antibiotics save lives and hearing — when in doubt, treat it as an emergency. Schematic.